Hypertension, Microvascular Pathology, and Prognosis After an Acute Myocardial Infarction

David Carrick, Caroline Haig, Annette M Maznyczka, Jaclyn Carberry, Kenneth Mangion, Nadeem Ahmed, Vannesa Teng Yue May, Margaret McEntegart, Mark C Petrie, Hany Eteiba, Mitchell Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmed Mahrous, Ify Mordi, Ian Ford, Aleksandra Radjenovic, Paul Welsh, Naveed Sattar, Kirsty Wetherall, Keith G Oldroyd, Colin Berry, David Carrick, Caroline Haig, Annette M Maznyczka, Jaclyn Carberry, Kenneth Mangion, Nadeem Ahmed, Vannesa Teng Yue May, Margaret McEntegart, Mark C Petrie, Hany Eteiba, Mitchell Lindsay, Stuart Hood, Stuart Watkins, Andrew Davie, Ahmed Mahrous, Ify Mordi, Ian Ford, Aleksandra Radjenovic, Paul Welsh, Naveed Sattar, Kirsty Wetherall, Keith G Oldroyd, Colin Berry

Abstract

The rationale for our study was to investigate the pathophysiology of microvascular injury in patients with acute ST-segment-elevation myocardial infarction in relation to a history of hypertension. We undertook a cohort study using invasive and noninvasive measures of microvascular injury, cardiac magnetic resonance imaging at 2 days and 6 months, and assessed health outcomes in the longer term. Three hundred twenty-four patients with acute myocardial infarction (mean age, 59 [12] years; blood pressure, 135 [25] / 79 [14] mm Hg; 237 [73%] male, 105 [32%] with antecedent hypertension) were prospectively enrolled during emergency percutaneous coronary intervention. Compared with patients without antecedent hypertension, patients with hypertension were older (63 [12] years versus 57 [11] years; P<0.001) and a lower proportion were cigarette smokers (52 [50%] versus 144 [66%]; P=0.007). Coronary blood flow, microvascular resistance within the culprit artery, infarct pathologies, inflammation (C-reactive protein and interleukin-6) were not associated with hypertension. Compared with patients without antecedent hypertension, patients with hypertension had less improvement in left ventricular ejection fraction at 6 months from baseline (5.3 [8.2]% versus 7.4 [7.6]%; P=0.040). Antecedent hypertension was a multivariable associate of incident myocardial hemorrhage 2-day post-MI (1.81 [0.98-3.34]; P=0.059) and all-cause death or heart failure (n=47 events, n=24 with hypertension; 2.53 [1.28-4.98]; P=0.007) postdischarge (median follow-up 4 years). Severe progressive microvascular injury is implicated in the pathophysiology and prognosis of patients with a history of hypertension and acute myocardial infarction. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02072850.

Keywords: atherosclerosis; hypertension; myocardial infarction; prognosis; reperfusion injury.

Figures

Figure 1.
Figure 1.
Two patients, one with a history of hypertension (A) and the other without (B) presented similarly with acute anterior ST-segment–elevation myocardial infarction and were treated by primary percutaneous coronary intervention (PCI) with stents. The antithrombotic therapies, including aspirin, clopidogrel, and unfractionated heparin, were similar. Each patient had normal antegrade flow in the culprit coronary artery (Thrombolysis In Myocardial Infarction grade 3) at the end of PCI. Multiparametric cardiovascular magnetic resonance (CMR) imaging was performed 2 d and 6 mo later. Top, A, Imaging obtained from a 52-year-old man with a history of current hypertension. The symptom-to-balloon time was 1.4 h. The coronary angiogram revealed a proximal occlusion of the left anterior descending artery. Blood pressure before coronary angioplasty was 200/125 mm Hg and measured 181/117 mm Hg postcoronary angioplasty. Two days later, CMR disclosed myocardial hemorrhage specifically revealed by T2* mapping (yellow arrows) and transmural infarction of the anteroseptal wall of the left ventricle (LV; yellow arrows) associated with microvascular obstruction revealed by contrast CMR. Invasive assessment of microvascular function using a diagnostic guidewire placed in the culprit coronary artery at the end of primary PCI indicated severe microvascular injury. The index of microvascular resistance measured 92 which is substantially increased (reference range <25). The initial infarct size was 38.9%, and the LV ejection fraction (LVEF) and LV end-diastolic volume indexed to body surface area (LVEDVi) were 48.5% and 90.2 mL/m2, respectively. Six months later, infarct size was 26.7% of LV mass, and the LVEDVi was 127 mL/m2. This is in-keeping with >20% in LVEDVi, that is, adverse remodeling. This patient went to have an unplanned admission for heart failure treatment on day 493 of follow-up. Bottom, B, Imaging obtained from a 58-year-old man with no prior history of hypertension. The symptom-to-balloon time was 2.2 h. The angiogram also revealed a proximal occlusion of the left anterior descending artery. Blood pressure before coronary angioplasty was 109/71 mm Hg and measured 99/60 mm Hg postcoronary angioplasty. Microvascular resistance in the culprit coronary artery was normal. Two days later, there was a small amount of microvascular obstruction as revealed by contrast-enhanced CMR (yellow arrows), and no evidence of myocardial hemorrhage (T2 star parametric map). The initial infarct size was 32.4%, and the LVEF and LVEDVi were 36.9% and 126.4 mL/m2, respectively. Six months later, infarct size was 15.2% of left ventricular mass, and the LVEDVi was 98.2 mL/m2. This patient had an uncomplicated clinical course.
Figure 2.
Figure 2.
Study flow diagram of the cohort study. CMR indicates cardiovascular magnetic resonance; and STEMI, ST-segment–elevation myocardial infarction.

References

    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. doi: 10.1016/S0140-6736(02)11911-8.
    1. Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485.
    1. British Heart Foundation. Cardiovascular Disease Statistics Factsheet (UK). . Accessed April 27, 2018.
    1. Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension. 2008;51:48–54. doi: 10.1161/HYPERTENSIONAHA.107.093682.
    1. Fresco C, Avanzini F, Bosi S, Franzosi MG, Maggioni AP, Santoro L, Bellanti G. Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with thrombolysis. GISSI-2 Investigators. Gruppo Italiano per lo Studio della, Sopravvivena nell’Infarto Miocardico. J Hypertens. 1996;14:743–750.
    1. Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, Espiner EA, Crozier IG, Yandle TG, Turner J. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 2002;39:1182–1188.
    1. Lee MG, Jeong MH, Lee KH, Park KH, Sim DS, Yoon HJ, Yoon NS, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Prognostic impact of diabetes mellitus and hypertension for mid-term outcome of patients with acute myocardial infarction who underwent percutaneous coronary intervention. J Cardiol. 2012;60:257–263. doi: 10.1016/j.jjcc.2012.06.003.
    1. De Luca G, van’t Hof AW, Huber K, et al. EGYPT cooperation. Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2013;112:1083–1086. doi: 10.1016/j.amjcard.2013.05.053.
    1. De Luca G, Dirksen MT, Spaulding C, et al. DESERT cooperation. Impact of hypertension on clinical outcome in STEMI patients undergoing primary angioplasty with BMS or DES: insights from the DESERT cooperation. Int J Cardiol. 2014;175:50–54. doi: 10.1016/j.ijcard.2014.04.180.
    1. Chen G, Hemmelgarn B, Alhaider S, Quan H, Campbell N, Rabi D. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction. Am J Cardiol. 2009;104:141–147. doi: 10.1016/j.amjcard.2009.02.048.
    1. Reinstadler SJ, Stiermaier T, Eitel C, Saad M, Metzler B, de Waha S, Fuernau G, Desch S, Thiele H, Eitel I. Antecedent hypertension and myocardial injury in patients with reperfused ST-elevation myocardial infarction. J Cardiovasc Magn Reson. 2016;18:80. doi: 10.1186/s12968-016-0299-1.
    1. De Luca G, Parodi G, Sciagrà R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antoniucci D. Impact of hypertension on infarct size in ST elevation myocardial infarction patients undergoing primary angioplasty. J Hypertens. 2013;31:2433–2437. doi: 10.1097/HJH.0b013e328364cbee.
    1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J., III. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.
    1. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med. 1970;72:813–822.
    1. Brush JE, Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol. 1992;19:809–815.
    1. Lehmann N, Erbel R, Mahabadi AA, Kälsch H, Möhlenkamp S, Moebus S, Stang A, Roggenbuck U, Strucksberg KH, Führer-Sakel D, Dragano N, Budde T, Seibel R, Grönemeyer D, Jöckel KH Heinz Nixdorf Recall Study Investigators. Accelerated progression of coronary artery calcification in hypertension but also prehypertension. J Hypertens. 2016;34:2233–2242. doi: 10.1097/HJH.0000000000001080.
    1. Sipahi I, Tuzcu EM, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, Crowe TD, Nissen SE. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833–838. doi: 10.1016/j.jacc.2006.05.045.
    1. Candemir B, Ertas FS, Ozdol C, Kaya CT, Kilickap M, Akyurek O, Atmaca Y, Kumbasar D, Erol C. Effect of hypertension on coronary remodeling patterns in angiographically normal or minimally atherosclerotic coronary arteries: an intravascular ultrasound study. Clin Exp Hypertens. 2012;34:432–438. doi: 10.3109/10641963.2012.665544.
    1. Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR, Jr, Lerman A. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol. 2000;35:1654–1660.
    1. Homsi R, Sprinkart AM, Gieseke J, Yuecel S, Meier-Schroers M, Luetkens J, Dabir D, Kuetting D, Marx C, Nadal J, Schild HH, Thomas D. 3D-Dixon cardiac magnetic resonance detects an increased epicardial fat volume in hypertensive men with myocardial infarction. Eur J Radiol. 2016;85:936–942. doi: 10.1016/j.ejrad.2016.02.016.
    1. Eitel I, Kubusch K, Strohm O, Desch S, Mikami Y, de Waha S, Gutberlet M, Schuler G, Friedrich MG, Thiele H. Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging. 2011;4:354–362. doi: 10.1161/CIRCIMAGING.110.960500.
    1. Carrick D, Haig C, Ahmed N, et al. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ Cardiovasc Imaging. 2016;9:e004148. doi: 10.1161/CIRCIMAGING.115.004148.
    1. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–2219. doi: 10.1093/eurheartj/eht151.
    1. Steg PG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619. doi: 10.1093/eurheartj/ehs215.
    1. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. phase I findings. N Engl J Med. 1985;312:932–936. doi: 10.1056/NEJM198504043121437.
    1. Gibson CM, Cannon CP, Daley WL, Dodge JT, Jr, Alexander B, Jr, Marble SJ, McCabe CH, Raymond L, Fortin T, Poole WK, Braunwald E. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–888.
    1. Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–130.
    1. Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;51:560–565. doi: 10.1016/j.jacc.2007.08.062.
    1. McGeoch R, Watkins S, Berry C, Steedman T, Davie A, Byrne J, Hillis S, Lindsay M, Robb S, Dargie H, Oldroyd K. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2010;3:715–722. doi: 10.1016/j.jcin.2010.04.009.
    1. Payne AR, Berry C, Doolin O, McEntegart M, Petrie MC, Lindsay MM, Hood S, Carrick D, Tzemos N, Weale P, McComb C, Foster J, Ford I, Oldroyd KG. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. J Am Heart Assoc. 2012;1:e002246. doi: 10.1161/JAHA.112.002246.
    1. Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG. Prognostic value of the index of microcirculatory resistance measured after primary percutaneous coronary intervention. Circulation. 2013;127:2436–2441. doi: 10.1161/CIRCULATIONAHA.112.000298.
    1. Carrick D, Haig C, Ahmed N, et al. Comparative prognostic utility of indexes of microvascular function alone or in combination in patients with an acute ST-segment-elevation myocardial infarction. Circulation. 2016;134:1833–1847. doi: 10.1161/CIRCULATIONAHA.116.022603.
    1. Sattar N, Murray HM, Welsh P, et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med. 2009;6:e1000099. doi: 10.1371/journal.pmed.1000099.
    1. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91. doi: 10.1186/1532-429X-15-91.
    1. Carrick D, Haig C, Rauhalammi S, et al. Pathophysiology of LV remodeling in survivors of STEMI: inflammation, remote myocardium, and prognosis. JACC Cardiovasc Imaging. 2015;8:779–789. doi: 10.1016/j.jcmg.2015.03.007.
    1. Giri S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, Simonetti OP. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56. doi: 10.1186/1532-429X-11-56.
    1. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging. 2011;4:269–278. doi: 10.1016/j.jcmg.2010.09.023.
    1. Kellman P, Arai AE, McVeigh ER, Aletras AH. Phase-sensitive inversion recovery for detecting myocardial infarction using gadolinium-delayed hyperenhancement. Magn Reson Med. 2002;47:372–383.
    1. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4:150–156. doi: 10.1016/j.jcmg.2010.11.015.
    1. Eitel I, Desch S, Fuernau G, Hildebrand L, Gutberlet M, Schuler G, Thiele H. Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:2470–2479. doi: 10.1016/j.jacc.2010.01.049.
    1. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey T, Hsu LY, Aletras AH, Arai AE. Magnetic resonance imaging delineates the ischemic area at risk and myocardial salvage in patients with acute myocardial infarction. Circ Cardiovasc Imaging. 2010;3:527–535. doi: 10.1161/CIRCIMAGING.109.900761.
    1. Payne AR, Casey M, McClure J, McGeoch R, Murphy A, Woodward R, Saul A, Bi X, Zuehlsdorff S, Oldroyd KG, Tzemos N, Berry C. Bright-blood T2-weighted MRI has higher diagnostic accuracy than dark-blood short tau inversion recovery MRI for detection of acute myocardial infarction and for assessment of the ischemic area at risk and myocardial salvage. Circ Cardiovasc Imaging. 2011;4:210–219. Doi: 10.1161/CIRCIMAGING.110.960450.
    1. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171–2179.
    1. Thygesen K, Alpert JS, Jaffe AS, et al. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–2035. doi: 10.1161/CIR.0b013e31826e1058.
    1. Hicks KA, Tcheng JE, Bozkurt B, et al. American College of Cardiology; American Heart Association. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). Circulation. 2015;132:302–361. doi: 10.1161/CIR.0000000000000156.
    1. Reinstadler SJ, Eitel C, Fuernau G, de Waha S, Desch S, Mende M, Metzler B, Schuler G, Thiele H, Eitel I. Association of smoking with myocardial injury and clinical outcome in patients undergoing mechanical reperfusion for ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging. 2017;18:39–45. doi: 10.1093/ehjci/jew030.
    1. Wilmot KA, O’Flaherty M, Capewell S, Ford ES, Vaccarino V. Coronary heart disease mortality declines in the United States from 1979 through 2011: evidence for stagnation in young adults, especially women. Circulation. 2015;132:997–1002. Doi: 10.1161/CIRCULATIONAHA.115.015293.
    1. Symons R, Masci PG, Francone M, Claus P, Barison A, Carbone I, Agati L, Galea N, Janssens S, Bogaert J. Impact of active smoking on myocardial infarction severity in reperfused ST-segment elevation myocardial infarction patients: the smoker’s paradox revisited. Eur Heart J. 2016;37:2756–2764. doi: 10.1093/eurheartj/ehv738.
    1. Carrick D, Haig C, Ahmed N. Temporal evolution of myocardial hemorrhage and edema in patients after acute ST-segment elevation myocardial infarction: pathophysiological insights and clinical implications. J Am Heart Assoc. 2016;5:e002834. doi: 10.1161/JAHA.115.002834.
    1. Bulluck H, Rosmini S, Abdel-Gadir A. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling. Circ Cardiovasc Imaging. 2016;9:e004940. doi: 10.1161/CIRCIMAGING.116.004940.

Source: PubMed

Подписаться